R
Rosario García-Campelo
Researcher at University of A Coruña
Publications - 63
Citations - 8507
Rosario García-Campelo is an academic researcher from University of A Coruña. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 18, co-authored 51 publications receiving 7471 citations. Previous affiliations of Rosario García-Campelo include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell,Teresa Moran,Cristina Queralt,Rut Porta,Felipe Cardenal,Carlos Camps,Margarita Majem,Guillermo Lopez-Vivanco,Dolores Isla,Mariano Provencio,A. Insa,Bartomeu Massuti,José Luis González-Larriba,Luis Paz-Ares,Isabel Bover,Rosario García-Campelo,Miguel Angel Moreno,Silvia Catot,Christian Rolfo,Noemi Reguart,Ramon Palmero,Jose Miguel Sanchez,Roman Bastus,Clara Mayo,Jordi Bertran-Alamillo,Miguel Angel Molina,Jose Javier Sanchez,Miquel Taron +27 more
TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.
Journal ArticleDOI
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Rafael Rosell,Miguel Angel Molina,Carlota Costa,Sara Simonetti,Anna Gimenez-Capitan,Jordi Bertran-Alamillo,Clara Mayo,Teresa Moran,Pedro Mendez,Felipe Cardenal,Dolores Isla,Mariano Provencio,Manuel Cobo,A. Insa,Rosario García-Campelo,Noemi Reguart,Margarita Majem,Santiago Viteri,Enric Carcereny,R. Porta,Bartomeu Massuti,Cristina Queralt,Itziar de Aguirre,Jose Miguel Sanchez,Maria Sanchez-Ronco,Jose Luis Mate,Aurelio Ariza,Susana Benlloch,Jose Javier Sanchez,Trever G. Bivona,Charles L. Sawyers,Miquel Taron +31 more
TL;DR: Low BRCA1 levels neutralized the negative effect of the T790M mutation and were associated with longer progression-free survival to erlotinib.
Journal ArticleDOI
The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
Carlota Costa,Miguel Angel Molina,Ana Drozdowskyj,Ana Giménez-Capitán,Jordi Bertran-Alamillo,Niki Karachaliou,Radj Gervais,Bartomeu Massuti,Jia Wei,Teresa Moran,Margarita Majem,Enriqueta Felip,Enric Carcereny,Rosario García-Campelo,Santiago Viteri,Miquel Taron,Mayumi Ono,Petros Giannikopoulos,Trever G. Bivona,Rafael Rosell +19 more
TL;DR: Low-level pretreatment T790M mutations can frequently be detected and can be used for customizing treatment with T790m-specific inhibitors and can potentially be used as a biomarker of survival in EGFR-mutant NSCLC and for synthetic lethality therapies.
Journal ArticleDOI
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Margarita Majem,Oscar Juan,A. Insa,Noemí Reguart,Jose Manuel Trigo,Enric Carcereny,Rosario García-Campelo,Y. García,M. Guirado,Mariano Provencio +9 more
TL;DR: New treatments mean that the authors must reconsider what should be done in oligometastatic disease where local treatment attains greater value, and it is important to evaluate each treatment alternative in accordance with scientific evidence.